NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

August 15, 2023

A panel of experts on the treatment of non–small cell lung cancer (NSCLC) discuss the role of biomarker testing and review testing strategies.

August 10, 2023

The panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.

August 10, 2023

An overview of ongoing research in the endometrial cancer treatment space.

August 03, 2023

The expert panel reviews the KEYNOTE-775 trial, which focused on lenvatinib and pembrolizumab in advanced endometrial cancer.

August 03, 2023

A panel of gynecologic oncologists review the PHAEDRA study and discuss the overall treatment landscape for endometrial cancer.

July 31, 2023

David R. Wise, MD, PhD, discusses key trials establishing the benefit of hormone therapy– or chemotherapy-based doublet therapy for patients with metastatic hormone-sensitive prostate cancer

July 28, 2023

Whitfield B. Growdon, MD, expands on the FDA’s decision to withdraw the later-line indication of olaparib for patients with BRCA-mutated ovarian cancer.

July 27, 2023

Experts on endometrial cancer review the NRG-GY018 and RUBY clinical trials.

July 27, 2023

The expert panel switches its focus to endometrial cancer and discusses recent data from clinical trials.

July 20, 2023

Expert gynecologic oncologists react to data from the MIRASOL trial, which studied mirvetuximab in patients with platinum-resistant ovarian cancer.

July 20, 2023

A panel of experts on ovarian cancer review ongoing trials on maintenance therapies for recurrent ovarian cancer.

July 13, 2023

A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.

July 13, 2023

Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.

July 06, 2023

A comprehensive overview of recent clinical trial data on PARP inhibitors in the first-line maintenance setting in ovarian cancer presented at ASCO 2023.

July 06, 2023

An expert panel highlights current unmet needs in the maintenance setting for ovarian cancer.

June 29, 2023

Experts on ovarian cancer discuss germline and somatic testing practices and provide clinical insights on factors that influence treatment decisions.

June 29, 2023

A panel of expert gynecologic oncologists introduce themselves and review frontline maintenance treatment options in ovarian cancer.

June 17, 2023

Michael Shusterman, MD, expands on the need for accurate early detection methods in solid tumors for which there aren’t proper surveillance tests, advantages of the unique methylation sequencing technique harnessed by this novel assay, and more.

May 31, 2023

David R. Wise, MD, PhD, discusses considerations for the use of doublet or triplet regimens for the treatment of patients with prostate cancer.

May 31, 2023

Whitfield B. Growdon, MD, shares the potential implications of first-line PARP maintenance in newly diagnosed ovarian cancer, the importance of treating patients with effective therapies as early as possible, and where combination regimens could fit into the treatment paradigm going forward.